Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology

Barak Zafrir, Nabeeh Salman, Maria G. Crespo-Leiro, Stefan D. Anker, Andrew J. Coats, Roberto Ferrari, Gerasimos Filippatos, Aldo P. Maggioni, Alexandre Mebazaa, Massimo Francesco Piepoli, Frank Ruschitzka, Maria J. Paniagua-Martin, Javier Segovia, Cecile Laroche, and Offer Amir, on behalf of the Heart Failure Long-Term Registry Investigators

Following the publication of Zafrir et al.1 some errors were identified in the companies listed in the Funding section, and the period of their involvement. The Funding section should read:

“Since the start of EORP, the following companies have supported the programme: Abbott Vascular Int. (2011–2014), Amgen Cardiovascular (2009–2018), AstraZeneca (2014–2017), Bayer (2009–2018), Boehringer Ingelheim (2009–2016), Boston Scientific (2009–2012), The Bristol Myers Squibb and Pfizer Alliance (2011–2016), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2011–2017), Gedeon Richter Plc. (2014–2017), Menarini Int. Op. (2009–2012), MSD-Merck & Co. (2011–2014), Novartis Pharma AG (2014–2017), ResMed (2014–2016), Sanofi (2009–2011), SERVIER (2009–2018).”